To date, a variety of immune checkpoint inhibitors (ICIs) have been approved by the Food and Drug Administra- tion (FDA) for clinical application [3]. However, the low response rate, innate or acquired drug resistance and immunotherapy-related adverse events (irAEs) challenge the utility of ...
Responders (R, with a decreased tumor size or SD > 6 months) had greater baseline frequencies of CD33hi classical mono- cytes (CD33hi cMo, p = 0.014) and C D9+ nonclassical monocytes (CD9+ nMo, p = 0.012) than non-responding (NR) patients (Fig....